

Special Issue

Immune Response and Vaccine Strategies against SARS-CoV-2

Message from the Guest Editors

The COVID-19 pandemic made us realize the importance of vaccines in protecting humans from unprecedented carnage caused by novel pathogens, especially fast-spreading respiratory viruses. We were fortunate to develop initial vaccine candidates against SARS-CoV-2 in an astonishingly short time. However, the virus has posed a formidable challenge through its constant antigenic drift and shift to evade vaccine-mediated and natural immunity. The durability of vaccine response has been another challenge, as the antibody responses against SARS-CoV-2 have been particularly short-lived. To develop better vaccines, it is crucial to understand the immune response against SARS-CoV-2, the immune correlates of protection, the determinants of the longevity of the immune response, and viral strategies to evade host immunity. In this proposed Special Issue, we will be inviting research articles and reviews from scientists across the globe specializing in this subject.

Guest Editors

Dr. Shashank Tripathi

Microbiology & Cell Biology, Indian Institute of Science, Bangalore, India

Dr. Kesavardana Sannula

Biochemistry, Indian Institute of Science, Bangalore, India

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/153446

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).